Monte Rosa Therapeutics (GLUE) News Today $10.68 +0.02 (+0.19%) As of 12:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Monte Rosa Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Monte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock Up3 hours ago | rttnews.comMonte Rosa Therapeutics Announces Novartis Initiates Phase 2 Study of MRT-6160 in Psoriatic ArthritisOctober 28 at 7:31 AM | quiverquant.comQMonte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)October 28 at 7:00 AM | globenewswire.comCritical Contrast: Monte Rosa Therapeutics (NASDAQ:GLUE) and CRISPR Therapeutics (NASDAQ:CRSP)October 25 at 4:29 AM | americanbankingnews.comAre options traders betting on a big move in Monte Rosa Therapeutics stock?October 23, 2026 | msn.com189,430 Shares in Monte Rosa Therapeutics, Inc. $GLUE Purchased by Assenagon Asset Management S.A.October 22, 2026 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Stock Jumps 8% - Here's What HappenedOctober 19, 2026 | marketbeat.comInvestors Buy Large Volume of Monte Rosa Therapeutics Call Options (NASDAQ:GLUE)October 19, 2026 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Raised to Hold at UBS GroupOctober 14, 2026 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Rated "Moderate Buy" by Sell-Side BrokeragesOctober 13, 2026 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 4.4% - What's Next?October 7, 2026 | marketbeat.comMonte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 StudyOctober 6, 2026 | marketbeat.comMonte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - SlideshowOctober 5, 2026 | seekingalpha.comBrokers Set Expectations for GLUE Q3 EarningsOctober 5, 2026 | marketbeat.comPiper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)October 4, 2026 | theglobeandmail.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comMonte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Raised to "Strong-Buy" at HC WainwrightOctober 2, 2026 | marketbeat.comMonte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk TranscriptOctober 1, 2026 | seekingalpha.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6% - What's Next?October 1, 2026 | marketbeat.comHC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price TargetOctober 1, 2026 | marketscreener.comMTranscript : Monte Rosa Therapeutics, Inc. - Special CallOctober 1, 2026 | marketscreener.comMMonte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 StudyOctober 1, 2026 | finance.yahoo.comMonte Rosa Shares Gain Ahead of Clinical Trial ReviewOctober 1, 2026 | marketwatch.comMonte Rosa plans mid-stage trials for anti-inflammatory agent after positive Phase 1 dataOctober 1, 2026 | seekingalpha.comHC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a buy ratingOctober 1, 2026 | msn.comMonte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD ...October 1, 2026 | finance.yahoo.comMonte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD RiskOctober 1, 2026 | globenewswire.comMonte Rosa Set To Report MRT-8102 Phase 1 Data In Cardiovascular Risk Study Today; Stock UpOctober 1, 2026 | rttnews.comMonte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease RiskSeptember 30, 2026 | globenewswire.comMonte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DESeptember 28, 2026 | marketbeat.comMonte Rosa to Receive $50 Million Milestone Payment From Novartis for Phase 2 Launch of MRT-6160September 8, 2026 | finance.yahoo.comMonte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)September 8, 2026 | globenewswire.comMonte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance SheetSeptember 3, 2026 | seekingalpha.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2026 | globenewswire.comMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comMonte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer StudyAugust 24, 2026 | finance.yahoo.comMonte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic...August 24, 2026 | markets.businessinsider.comMonte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate CancerAugust 24, 2026 | globenewswire.comMonte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesAugust 6, 2026 | finance.yahoo.comMonte Rosa’s MODeFIRe-1 Trial Pushes GLUE Into a Key Mid-Stage Prostate Cancer TestAugust 4, 2026 | tipranks.comMonte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipelineJuly 31, 2026 | seekingalpha.comMonte Rosa Therapeutics : GLUEJuly 21, 2026 | 247wallst.comAnalysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)July 14, 2026 | theglobeandmail.comMonte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 6,000 Shares of StockJuly 8, 2026 | insidertrades.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comInsider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 5,407 Shares of StockJuly 2, 2026 | insidertrades.comAfter a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?June 29, 2026 | finance.yahoo.comWells Fargo Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)June 26, 2026 | theglobeandmail.comInsider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) COO Sells $43,500.00 in StockJune 26, 2026 | insidertrades.com10 small-cap U.S. healthcare stocks with the strongest momentum gradesJune 24, 2026 | seekingalpha.com Monte Rosa Therapeutics Media Mentions By Week Monte Rosa Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼0.910.69▲Average Healthcare News Sentiment Monte Rosa Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼53▲GLUE Articles Average Week Monte Rosa Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views1,930-14% Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CDNA News ACAD News XENE News VKTX News AMLX News IDYA News PBLS News DNLI News RCUS News ELVN News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Monte Rosa Therapeutics dated 10/28/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
